Khanh Vu, MD
Radiation Oncology · Jamestown, NYNPI 1538425947
Payments from drug & device makers
Across 47 payments — averaging $53.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- AstraZeneca$184
- E.r. Squibb & Sons, L.L.C.$124
- Merck$120
- Johnson & Johnson$101
- Novartis$85
- plus $453 from 15 others
What the payments were for
- Travel & lodging$1,33653%
- Food & beverage$1,20147%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $1,471 |
| AstraZeneca(2 entities) | 4 | $184 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Merck | 5 | $120 |
| Johnson & Johnson | 5 | $101 |
| Novartis | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Caris MPI, Inc. | 2 | $36 |
| Novocure Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $34 |
| Tactile Systems Technology Inc | 1 | $33 |
| Exelixis Inc. | 1 | $28 |
| Blueprint Medicines Corporation | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| EMD Serono, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR System$1,301
- SpaceOAR VUE System - 10mL$135
- IMFINZI$125
- EMPLICITI$124
How this compares
$2,537 in reported general payments places this provider in the 75th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $180 |
| Tamsulosin Hcl | 21 | $174 |
| Lidocaine Hcl ViscousLidocaine Hcl | 16 | $143 |
| SsdSilver Sulfadiazine | 12 | $97 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Jamestown
- Narek ShaverdianNew York$9.8M
- Timothy ChanNew York$3.8M
- Chung ChungSyracuse$3.1M
- Brandon ImberNew York$2.8M
- Silvia FormentiNew York$2.7M
- Steven FinkelsteinSyracuse$2.6M
- Christopher BarkerNew York$2.5M
- Chandan GuhaBronx$1.6M
- Michael ZelefskyNew York$1.5M
- Eileen ConnollyNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.